| Symbol | ATNM |
|---|---|
| Name | ACTINIUM PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 PARK AVENUE,23RD FLOOR, NEW YORK, New York, 10017, United States |
| Telephone | (917) 415-1750 |
| Fax | — |
| — | |
| Website | https://www.actiniumpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001388320 |
| Description | Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML), which Actinium plans to advance with a potential strategic partner in the U.S. following completion of FDA interactions. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. Additional info from NASDAQ: |
New Form 3 - Actinium Pharmaceuticals, Inc. <b>Filed:</b> 2026-09-10 <b>AccNo:</b> 0001213900-26-098841 <b>Size:</b> 5 KB
Read moreNew Form 3 - Actinium Pharmaceuticals, Inc. <b>Filed:</b> 2026-09-10 <b>AccNo:</b> 0001213900-26-098842 <b>Size:</b> 5 KB
Read moreDirector Shetty Ajit 🟢 acquired 154.0K shares (1 derivative) of Actinium Pharmaceuticals, Inc. (ATNM) at $1.00 Transaction Date: Sep 02, 2026 | Filing ID: 097744
Read moreDirector Nicholson, C. David 🟢 acquired 157.0K shares (1 derivative) of Actinium Pharmaceuticals, Inc. (ATNM) at $1.00 Transaction Date: Sep 02, 2026 | Filing ID: 097745
Read moreDirector Almenoff June Sherie 🟢 acquired 45.0K shares (1 derivative) of Actinium Pharmaceuticals, Inc. (ATNM) at $1.00 Transaction Date: Sep 02, 2026 | Filing ID: 097742
Read moreDirector SETH SANDESH 🟢 acquired 2.9M shares (1 derivative) of Actinium Pharmaceuticals, Inc. (ATNM) at $1.00 ($1.1M) Transaction Date: Sep 02, 2026 | Filing ID: 097741
Read moreDirector Steinhart Richard I 🟢 acquired 157.0K shares (1 derivative) of Actinium Pharmaceuticals, Inc. (ATNM) at $1.00 Transaction Date: Sep 02, 2026 | Filing ID: 097740
Read moreDirector Chell Jeffrey W. 🟢 acquired 154.0K shares (1 derivative) of Actinium Pharmaceuticals, Inc. (ATNM) at $1.00 Transaction Date: Sep 02, 2026 | Filing ID: 097739
Read moreActinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
Read moreActinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplan… | Phase2 | Acute Leukemia | Not_Yet_Recruiting | 2026-01-01 | 2034-02-01 | ClinicalTrials.gov |
| NCT07015684 | 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSC… | Phase1 | Sickling Disorder Due to Hemoglobin S | Recruiting | 2025-04-28 | 2032-03-12 | ClinicalTrials.gov |
| NCT06768905 | IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL | Phase1 | Non Hodgkin Lymphoma | Recruiting | 2025-04-25 | 2030-05-01 | ClinicalTrials.gov |
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | Phase1 | Acute Myeloid Leukemia | Withdrawn | 2023-03-01 | 2024-09-01 | ClinicalTrials.gov |
| NCT03867682 | Venetoclax and Lintuzumab-Ac225 in AML Patients | Phase1 | Acute Myeloid Leukemia | Unknown | 2020-01-15 | 2024-06-01 | ClinicalTrials.gov |
| NCT02998047 | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | Phase1 | Refractory Multiple Myeloma | Terminated | 2016-12-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT02665065 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed … | Phase3 | Acute Myeloid Leukemia | Active_Not_Recruiting | 2016-06-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | Phase1 | AML | Completed | 2012-10-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT00672165 | Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoc… | Phase1 | Leukemia | Completed | 2005-07-01 | 2015-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Planar gamma imaging | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Exchange Transfusion | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Total Body Irradiation | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Campath | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Sirolimus | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| 131I-apamistmab | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Lintuzumab AC 225 | Other | Phase PHASE1 | Refractory Multiple Myeloma | TERMINATED | NCT02998047 |
| Azacitidine | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Lintuzumab-Ac225 | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| HCT | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Conventional Care | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Iomab-B | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Spironolactone | Other | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Furosemide (Phase 1 only) | Other | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Lintuzumab-Ac225 | Other | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Cytarabine (Phase 1 only) | Other | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Spironolactone | Other | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT03867682 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT03867682 |
| Lintuzumab-Ac225 | Other | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT03867682 |
| Planar gamma imaging | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Exchange Transfusion | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Total Body Irradiation | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Campath | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Sirolimus | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| 131I-apamistmab | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | Other | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Total Body Irradiation (TBI) | Other | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Cyclophosphamide | Other | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Fludarabine | Other | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| 131I-apamistamab | Other | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | BIOLOGICAL | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Total Body Irradiation (TBI) | RADIATION | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Cyclophosphamide | DRUG | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Fludarabine | DRUG | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| 131I-apamistamab | DRUG | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Planar gamma imaging | RADIATION | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Exchange Transfusion | PROCEDURE | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Total Body Irradiation | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Campath | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Sirolimus | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| 131I-apamistmab | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| CAR-T cell | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Azacitidine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Venetoclax | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Lintuzumab AC 225 | DRUG | Phase PHASE1 | Refractory Multiple Myeloma | TERMINATED | NCT02998047 |
| HCT | PROCEDURE | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Conventional Care | DRUG | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Iomab-B | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Spironolactone | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT03867682 |
| Furosemide (Phase 1 only) | DRUG | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Lintuzumab-Ac225 | BIOLOGICAL | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Cytarabine (Phase 1 only) | DRUG | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 | BIOLOGICAL | Phase PHASE1 | Leukemia | COMPLETED | NCT00672165 |